

1 **Monocyte CD169 expression as a biomarker in the early diagnosis of**  
2 **COVID-19**

3

4 Anne-Sophie Bedin<sup>1</sup>, Alain Makinson<sup>2</sup>, Marie-Christine Picot<sup>3</sup>, Frank Mennechet<sup>1</sup>, Fabrice Malergue<sup>4</sup>,  
5 Amandine Pisoni<sup>5</sup>, Esperance Nyiramigisha<sup>6</sup>, Lise Montagnier<sup>6</sup>, Karine Bollore<sup>1</sup>, Ségolène Debieesse<sup>1</sup>,  
6 David Morquin<sup>2</sup>, Penelope Bourgoïn<sup>4</sup>, Nicolas Veyrenche<sup>5</sup>, Constance Renault<sup>1</sup>, Vincent Foulongne<sup>5</sup>,  
7 Caroline Bret<sup>7</sup>, Arnaud Bourdin<sup>8</sup>, Vincent Le Moing<sup>2</sup>, Philippe Van de Perre<sup>5</sup>, Edouard Tuailon<sup>5</sup>.

8

9 <sup>1</sup>Pathogenesis and Control of Chronic Infections, Montpellier University, INSERM, EFS; Montpellier,  
10 France.

11 <sup>2</sup>INSERM U1175/IRD UMI 233, IRD, Montpellier University and Department of Infectious Diseases  
12 Montpellier University Hospital, Montpellier, France.

13 <sup>3</sup>INSERM, Clinical Research and Epidemiology Unit 1411, Montpellier University and Montpellier  
14 University Hospital, Montpellier, France.

15 <sup>4</sup>Department of Research and Development, Immunotech-Beckman Coulter, Marseille, France.

16 <sup>5</sup>Pathogenesis and Control of Chronic Infections, INSERM U1058/EFS; Montpellier University, and  
17 Laboratory of Virology, Montpellier University Hospital, France.

18 <sup>6</sup>Laboratory of Virology, Montpellier University Hospital, France.

19 <sup>7</sup>Laboratory of Hematology, Montpellier University Hospital, France.

20

21

22    **Abstract**

23    We assessed the expression of the cell adhesion molecule Sialoadhesin (CD169), a type I interferon-  
24    inducible receptor, on monocytes (mCD169) in 53 adult patients admitted to the hospital during the  
25    COVID-19 outbreak for a suspicion of SARS-CoV-2 infection. mCD169 was strongly overexpressed in  
26    30 out of 32 (93.7%) confirmed COVID-19 cases, compared to three out of 21 (14.3%) patients for  
27    whom the diagnosis of COVID-19 was finally ruled out. mCD169 was associated with the plasma  
28    interferon alpha level and thrombocytopenia. mCD169 testing may be helpful for the rapid triage of  
29    suspected COVID-19 patients during an outbreak.

30

31 Like the rest of Europe, France has been severely affected by the COVID-19 epidemic. Early  
32 identification and prompt diagnosis of SARS-CoV-2 infection are of prime importance for the  
33 outcome of patients. It is also mandatory to avoid unnecessary and time-consuming interventions for  
34 patients who do not have COVID-19 but who may have another serious illness requiring appropriate  
35 care.

36 Type I interferons (IFN) are important factors for homeostasis of the immune response and play a key  
37 role in antiviral immunity<sup>12</sup>. A robust type-I IFN response is critical in the early phase of SARS-CoV-2  
38 infection to limit SARS-CoV-2 replication and avoid a severe clinical outcome<sup>3</sup>. CD169, also known as  
39 sialoadhesin or Siglec-1, is constitutively expressed at low levels on monocytes, but its expression  
40 rises dramatically when monocytes become stimulated by IFN $\alpha$  and all other type I IFNs<sup>1-4</sup>. Studies  
41 have reported that monocyte CD169 (mCD169) overexpression is associated with acute viral  
42 infections<sup>5-7</sup>. Furthermore, a subset of CD169 lung-resident macrophages that have  
43 immunoregulatory functions and proliferate after influenza infection has recently been described<sup>8</sup>.

44 In March 2020, Montpellier University Hospital reorganized its service delivery in response to the  
45 COVID-19 outbreak. A specific care system strengthened the triage, diagnosis and hospitalization of  
46 patients with suspected COVID-19. In this prospective observational study conducted during the  
47 COVID-19 outbreak, we evaluated mCD169 expression for the identification of SARS-CoV-2 infection  
48 in patients at hospital admission.

49 Among 162 patients admitted in the respiratory emergency unit from 15 March to 05 April 2020, 53  
50 (32.7%) were randomly selected and tested for mCD169 expression (Supplemental Fig.1). Thirty-two  
51 of these patients tested positive for SARS-CoV-2 RNA (31 on the first nasopharyngeal sample, one on  
52 the third sample), and 21 tested negative. Thirty patients with a confirmed diagnosis of COVID-19  
53 had a mCD169 expression level above the positivity threshold (93.7%) (Fig.1.A). In contrast, only  
54 three of the 21 patients uninfected by SARS-CoV-2 had a mCD169 overexpression (14.3%). Neutrophil  
55 CD64 (nCD64) was assessed as a marker for systemic bacterial infection<sup>9</sup>. High nCD64 expression was

56 observed in seven out of 21 (33.3%) COVID-19 negative patients (Fig.1.B). Bacterial infection was  
57 microbiologically confirmed for all but one of these patients (6/7). Four out of 32 (12.5%) confirmed  
58 COVID-19 cases also had nCD64 expression over the threshold; two of them had confirmation of a  
59 bacterial infection. A higher median expression of CD38<sup>bright</sup> on CD8+ T-cells also was observed in the  
60 COVID-19 confirmed group compared to the COVID-19 uninfected group. CD38 on CD8+ T-cells is a  
61 robust marker of inflammation, overexpressed in viral infections<sup>10</sup>. However, this marker has a  
62 limited capacity to identify COVID-19 cases since CD38<sup>bright</sup> on CD8+ T-cells was at a normal level in  
63 11 COVID-19 confirmed cases (34.3%) (Fig.1.C). The level of mCD169 was inversely correlated with  
64 the CT (Cycle time detection) value of the SARS-CoV-2 PCR, suggesting that the immunological  
65 marker was associated with the level of virus replication ( $R^2= 0.24$ ) (Fig.1.E). At hospital admission,  
66 mCD169 was not associated with the amount of time following the onset of symptoms in COVID-19  
67 confirmed patients (Fig.1.D). We did not observe a difference in mCD169 expression between  
68 patients who required a stay in intensive care units, patients with mild forms of COVID-19, or  
69 patients who died. The mCD169 level was correlated with the concentration of IFN $\alpha$  in plasma and  
70 thrombocytopenia, but not with the CRP concentration, lymphopenia or neutrophil count  
71 (Supplemental Fig. 2).

72 The test accuracy of mCD169 to predict COVID-19 infection was studied by means of a receiver  
73 operating characteristic curve (ROC curve) and compared to the CRP level (Supplemental data 3). The  
74 sensitivity and specificity at the optimal operating point were 97% and 80%, respectively, with an  
75 Area under the ROC Curve (AUC) of 0.95. CRP had a sensitivity and specificity of 94% and 33%,  
76 respectively, with an AUC of 0.58. To investigate whether mCD169 could complement serological  
77 testing, we retrospectively assessed anti-SARS-CoV-2 nucleocapsid IgG. Among the confirmed COVID-  
78 19 cases, seven patients also tested positive for SARS-CoV-2 IgG at the time of hospital admission.  
79 These patients had a lower mCD169 level than patients who tested negative for anti-SARS-CoV-2 IgG  
80 ( $p=0.0084$ ), suggesting that high mCD169 is associated with active SARS-CoV-2 infection, before  
81 seroconversion (Fig.1.F).

82 A second blood sample was taken from 18 confirmed COVID-19 patients before they were discharged  
83 from the hospital to assess changes in mCD169 levels. A concomitant decay of mCD169 and IFN $\alpha$  was  
84 observed in 15 out of the 18 cases (83%), with five of them achieving a normalization of mCD169  
85 expression (Fig. 2). Two patients exhibited a rise and one a stable mCD169 expression. Of note, the  
86 platelet count increased between the first and second time points in all of the confirmed COVID-19  
87 patients.

88 The rapid identification of COVID-19 is a major challenge for emergency units, especially when a  
89 hospital has to cope with 200 to 300 suspected cases but a low number of real infections.  
90 Montpellier University Hospital has been strongly impacted by the COVID-19 crisis although the  
91 region around Montpellier reported a relatively low proportion of COVID-19 cases during the peak of  
92 the epidemic, which occurred in France between March and April. This was due to the dynamics of  
93 the spread of the disease in France. The first cases of SARS-CoV-2 were reported in the country in  
94 mid-February 2020<sup>11</sup>. The spread of the virus accelerated thereafter, in particular from a large, four-  
95 day long religious meeting that began on February 17 in a city located 650 km from our hospital.  
96 Since France went into lockdown on 17 March 2020, the COVID-19 burden in the Montpellier region  
97 has been very different compared to the harder hit northeastern part of the country. The  
98 seroprevalence (95% CI) at this end of the wave<sup>12</sup> was estimated at 1.9% (1.2-3.3) in the Montpellier  
99 region versus 9.1% (6.0-14.6) in the northeast. Consequently, even at the peak incidence of SARS-  
100 CoV-2 (when the study was conducted), only some of the patients suspected of COVID-19 and  
101 admitted in dedicated care units had a confirmed diagnosis of SARS-CoV-2 infection. For the  
102 remainder, the diagnosis of COVID-19 needed to be rapidly ruled out following hospital admission. To  
103 our knowledge, the present study is the first to evaluate the value of mCD169 measurements in the  
104 rapid identification of COVID-19. We found that mCD169 could predict SARS-CoV-2 infection at  
105 hospital admission during the outbreak. This biomarker could be relevant for triage and rapid  
106 therapeutic decision in patients suspected of acute viral infections since mCD169 can be  
107 overexpressed in other infections responsible of outbreaks such as influenza or dengue fever.

108 Our study has some limitations. First, we did not included subjects with negative PCR results but later  
109 COVID-19 confirmation by radiological or serological findings. Second, the small number of subjects  
110 did not allow us to explore the relationship between the dynamic changes of mCD169 and patients'  
111 outcomes. Finally, we could not confirm our findings through a large-scale survey due to the rapid  
112 decrease in admissions of suspected COVID-19 cases in our hospital after April.

113 In conclusion, mCD169 may be a sensitive marker for the rapid triage of patients suspected of having  
114 COVID-19. This type I IFN-inducible receptor is strongly overexpressed on monocytes during the early  
115 phase of the SARS-CoV-2 infection, and remains elevated in patients admitted to the hospital during  
116 the second week following the onset of symptoms. The assessment of mCD169 may complement  
117 viral and serological methods to improve the diagnosis of COVID-19. Alongside RT-PCR and  
118 serological testing, mCD169 may contribute to preserving the medical capacities of emergency  
119 departments by favoring the rapid orientation of patients with possible COVID-19. The value of  
120 leukocytes activation markers, including mCD169 and nCD64, in the diagnosis of acute infection  
121 needs to be evaluated during viral outbreaks in clinical studies. The development of fully automated  
122 tests for these markers may be crucial to prepare for future potential epidemics.

123

## 124 **Material and methods**

125 This study was conducted by the University Hospital of Montpellier, the 7<sup>th</sup> largest hospital in France,  
126 during the peak of the COVID-19 epidemic between 15 March and 5 April 2020. The population of  
127 this prospective, observational study consisted of consecutive adult patients suspected of SARS-CoV-  
128 2 infection and hospitalized in the medical units dedicated to the diagnosis of COVID-19. There was a  
129 limit of 15 patients enrolled per day due to the limited capacity of the laboratory to perform  
130 cytometer analysis during the outbreak. The patients satisfied the criteria of the national guidelines  
131 for RT-PCR testing, which at the time of the study consisted of the presence of symptoms of  
132 pneumonia or having risk factors associated with severe COVID-19. Cases for whom the diagnosis of

133 COVID-19 could not be confirmed or dismissed based on RT-PCR results were excluded from the  
134 study. Of the 52 patients recruited, 32 patients were confirmed to be SARS-CoV-2 positive using a  
135 deep throat-swab, while 21 tested negative. Among the confirmed cases, 18 patients had a second  
136 cytometry analysis during their hospitalization. The median age of the patients was 64 years (IQR,  
137 51–78.5 years) and 54.7% were male (Supplementary Table 1).

138

### 139 **Positive controls and thresholds**

140

141 We assessed the expression of mCD169, nCD64 and CD38<sup>bright</sup> on CD8 T-cells in 30 healthy controls to  
142 establish a threshold based on the median + 3SD. The thresholds were: 3.51 for the mCD169 MFI  
143 ratio, 4.59 for the nCD64 MFI, and 9.06% for CD38<sup>bright</sup>. The nCD64 threshold was controlled on 10  
144 clinical samples collected from patients with microbiologically confirmed bacterial infections (median  
145 (IQR) = 8.44; (5.77-11.37)).

### 146 **SARS-CoV-2 RNA testing**

147 SARS-CoV-2 RNA extraction from nasopharyngeal swabs (Sigma Virocult, Medical Wire Instrument,  
148 Corsham, UK) was done using the QIAamp Viral RNA Mini Kit on the QIA Symphony platform,  
149 following the manufacturer's instructions. SARS-CoV-2 RNA was assessed using a RT-PCR targeting  
150 RNA-dependent RNA polymerase (RdRp) as previously described<sup>13</sup>.

### 151 **Flow cytometry**

152 10 µl of EDTA sample was simultaneously lysed with 500 µL of Versalyse lysing solution and stained  
153 with CD64-CD169/infections dried custom mixture, composed of anti-CD169-phycoerythrin (PE)  
154 (clone 7-239) and anti-CD64-Pacific Blue (PB) (clone 22). A second panel was used containing CD45-  
155 FITC, CD8-ECD, CD3 PC5, CD4-RD1 (CYTO-STAT tetraCHROME) and CD38-PB. Samples were  
156 incubated at room temperature for 30 minutes, in the dark. All products or custom products came  
157 from Beckman Coulter Inc, (Brea, CA). We acquired on a 3-laser, 10-color Navios flow cytometer and

158 analyzed using Kaluza Software version 2.1 (both from Beckman Coulter Brea, CA Inc). The stability of  
159 the instrument was monitored and validated daily with Flow-Check Fluorospheres used to verify  
160 instrument optical alignment and fluidics, and Flow-Set Fluorospheres for the quantitative analysis of  
161 human leukocytes.

#### 162 **Interferon alpha plasma concentration**

163 Plasma samples were stored at – 80 °C until processing. Interferon alpha (IFN- $\alpha$ ) was quantified using  
164 a multiplex microsphere assay (Invitrogen Human Inflammation 20-plex ProcartaPlex Panel, Marne-  
165 La-Vallée, France) on a Luminex apparatus (MAGPIX, Thermo Fisher Scientific, Massachusetts, USA)  
166 following manufacturer’s instructions.

#### 167 **Serology**

168 Plasma samples were tested for IgG antibodies directed against SARS-CoV-2 nucleocapsid using a CE-  
169 marked ELISA (ID.Vet, ID screen® SARS-CoV-2-N, Montpellier, France) as previously described<sup>11</sup>. Each  
170 sample is treated as a ratio: S/P (Sample/positive control) expressed in percentile (%):  $S/P \% = (\text{Optic}$   
171  $\text{density (OD) of sample} - \text{OD negative control}) / (\text{OD positive control} - \text{OD negative control}) \times 100$ . S/P  
172 > 60% is positive and < 60% is negative.

#### 173 **Statistical analysis**

174 Data were analysed and illustrated using Excel 2016 (Microsoft Corp, Redmond, Washington) and  
175 Prism 7 (GraphPad Software Inc, La Jolla, California) software. To determine statistical significance  
176 between the two groups (ie. CD169 COVID+ vs COVID -), unpaired Student’s two-tailed t-test or non-  
177 parametric Mann-Whitney test was applied, according to the distribution. Correlations were  
178 analysed using Pearson or Spearman’s rank test according of the normality of the data set. To  
179 determine statistical significance between two groups (i.e., CD169 COVID + versus COVID -), an  
180 unpaired Student’s two-tailed t-test was applied.

181 A *p* value of <0.05 was considered statistically significant.

182 **Acknowledgements**

183 This work was supported by the Montpellier University Hospital, Muse I-SITE Program grant,  
184 University of Montpellier. The funders had no role in the design of the study, the collection or  
185 analysis of data or the decision to publish. We thank S. Groc, S. Marie, and C. Niel for technical  
186 assistance.

187 **Contributions**

188 A.S.B. planned and supervised laboratory testing, analyzed the data and wrote the manuscript. A.M,  
189 D.M, A.B, V.L.M managed patients and evaluated clinical data. A.P, L.M., E.M, K.B, S.D., V.F, and C.B  
190 performed laboratory testing. F.M wrote the manuscript. M.C.P. evaluated clinical data and  
191 supervised statistical analysis. P.Vd.P. designed the study and wrote the manuscript. E.T. designed  
192 and conceptualized the study, analyzed the data and wrote the manuscript.

193 **Ethical approval statement**

194 All patients were included in the COVIDotheque cohort (ClinicalTrials.gov Identifier: NCT04347850)  
195 and provided informed consent for the use of their data and clinical samples for the study.  
196 Institutional review board clearance for the scientific use of patient data has been granted by the  
197 Institutional of Montpellier University Hospital and Ile de France III ethical committee (n°2020-  
198 A00935-34).

199 **Corresponding authors**

200 Correspondence to Anne-Sophie Bedin or Edouard Tuillon.

201 **References**

- 202 1. Muller, U. *et al.* Functional role of type I and type II interferons in antiviral defense. *Science* **264**,  
203 1918–1921 (1994).
- 204 2. McNab, F., Mayer-Barber, K., Sher, A., Wack, A. & O’Garra, A. Type I interferons in infectious  
205 disease. *Nat. Rev. Immunol.* **15**, 87–103 (2015).
- 206 3. Blanco-Melo, D. *et al.* Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19.  
207 *Cell* **181**, 1036-1045.e9 (2020).
- 208 4. Pino, M. *et al.* HIV-1 immune activation induces Siglec-1 expression and enhances viral trans-  
209 infection in blood and tissue myeloid cells. *Retrovirology* **12**, 37 (2015).
- 210 5. Kim, W.-K. *et al.* Increased Expression of CD169 on Blood Monocytes and Its Regulation by Virus  
211 and CD8 T Cells in Macaque Models of HIV Infection and AIDS. *AIDS Res. Hum. Retroviruses* **31**,  
212 696–706 (2015).
- 213 6. Bourgoin, P. *et al.* A novel one-step extracellular staining for flow cytometry: Proof-of-concept on  
214 sepsis-related biomarkers. *J. Immunol. Methods* **470**, 59–63 (2019).
- 215 7. Bourgoin, P. *et al.* Flow cytometry evaluation of infection-related biomarkers in febrile subjects in  
216 the emergency department. *Future Microbiol.* **15**, 189–201 (2020).
- 217 8. Ural, B. B. *et al.* Identification of a nerve-associated, lung-resident interstitial macrophage subset  
218 with distinct localization and immunoregulatory properties. *Sci. Immunol.* **5**, eaax8756 (2020).
- 219 9. Cid, J., Aguinaco, R., Sánchez, R., García-Pardo, G. & Llorente, A. Neutrophil CD64 expression as  
220 marker of bacterial infection: A systematic review and meta-analysis. *J. Infect.* **60**, 313–319 (2010).
- 221 10. Glaría, E., Valledor, A. F. Roles of CD38 in the Immune Response to Infection. *Cells.* **16**, 228-  
222 (2020).
- 223 11. Lescure, F.-X. *et al.* Clinical and virological data of the first cases of COVID-19 in Europe: a case  
224 series. *Lancet Infect. Dis.* S1473309920302000 (2020) doi:10.1016/S1473-3099(20)30200-0.

- 225 12. Tuailon, E. *et al.* Detection of SARS-CoV-2 antibodies using commercial assays and  
226 seroconversion patterns in hospitalized patients. *J. Infect.* S0163445320303765 (2020)  
227 doi:10.1016/j.jinf.2020.05.077.
- 228 13. Corman, V. M. *et al.* Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.  
229 *Eurosurveillance* **25**, (2020).  
230

231 **Figure 1. CD169 expression on monocytes in patients admitted in COVID-19 hospital units with a**  
232 **diagnosis of SARS-CoV-2 infection confirmed or ruled out**

233 **A.** CD169 Median of fluorescence intensity (MFI) ratio (CD169 on monocyte / CD169 on  
234 lymphocytes). Healthy controls (HC) are indicated by black diamonds; patients tested negative for  
235 SARS-CoV-2 infection (COVID -) are indicated by open squares or black squares in patients with  
236 bacterial microbiologically confirmed infections; SARS-CoV-2 confirmed infection (COVID +) are open  
237 circles for mild and black circles for severe COVID-19. The threshold of CD169 MFI ratio is indicated  
238 by the dotted line: 3.51. \*\*\*\* $p < 0.0001$ ; \* $p < 0.05$ .

239 **B.** CD64 MFI ratio (CD64 on neutrophil granulocyte / CD64 on lymphocytes), threshold: 4.59.

240 **C.** Percentage of CD38<sup>bright</sup> CD8+ T cells; threshold: 9.06%.

241 **D.** CD169 MFI ratio at hospital admission according to time elapsed from the first symptoms.

242 **E.** Correlation between CD169 MFI ratio and CT value of the SARS-CoV-2 reverse-transcriptase- real-  
243 time polymerase chain reaction (CT-PCR) in COVID-19 confirmed patients.


244 **F.** Expression of CD169 on monocyte according to serological status for anti-SARS-CoV-2 IgG at  
245 hospital admission.

246 **G.** Interferon alpha plasma concentration at hospital admission in patients with a diagnosis of SARS-  
247 CoV-2 infection confirmed or ruled out.

248

249 **Figure 2. Evolution of CD169 MFI ratio, IFN $\alpha$  plasma concentration and platelet count on repeated**  
250 **testing in 18 COVID-19 confirmed patients**

251 CD169 MFI ratio is indicated by black circles, IFN $\alpha$  plasma concentration by grey squares and  
252 platelets count by triangles. Days from onset of symptoms are indicated for the first and second time  
253 points.



**Figure 1. CD169 expression on monocytes in patients admitted in COVID-19 hospital units with a diagnosis of SARS-CoV-2 infection confirmed or ruled out**

- A. CD169 Median of fluorescence intensity (MFI) ratio (CD169 on monocyte / CD169 on lymphocytes). Healthy controls (HC) are indicated by black diamonds; patients tested negative for SARS-CoV-2 infection (COVID -) are indicated by open squares or black squares in patients with bacterial microbiologically confirmed infections; SARS-CoV-2 confirmed infection (COVID +) are open circles for mild and black circles for severe COVID-19. The threshold of CD169 MFI ratio is indicated by the dotted line: 3.51. \*\*\*\* $p < 0.0001$ ; \* $p < 0.05$ .
- B. CD64 MFI ratio (CD64 on neutrophil granulocyte / CD64 on lymphocytes), threshold: 4.59.
- C. Percentage of CD38<sup>bright</sup> CD8+ T cells; threshold: 9.06%.
- D. CD169 MFI ratio at hospital admission according to time elapsed from the first symptoms.
- E. Correlation between CD169 MFI ratio and CT value of the SARS-CoV-2 reverse-transcriptase- real-time polymerase chain reaction (CT-PCR) in COVID-19 confirmed patients.
- F. Expression of CD169 on monocyte according to serological status for anti-SARS-CoV-2 IgG at hospital admission.
- G. Interferon alpha plasma concentration at hospital admission in patients with a diagnosis of SARS-CoV-2 infection confirmed or ruled out.

Figure 2.




Figure 2. Evolution of CD169 MFI ratio, IFN $\alpha$  plasma concentration and platelet count on repeated testing in 18 COVID-19 confirmed patients

CD169 MFI ratio is indicated by black circles, IFN $\alpha$  plasma concentration by grey squares and platelets count by triangles. Days from onset of symptoms are indicated for the first and second time points.